Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

AGENNIX INCORPORATED

Home Clinical Trial Sponsors and OrganizationsAGENNIX INCORPORATED

AGENNIX INCORPORATED

581 Main St Ste 640, Woodbridge, New Jersey, United States

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

18

15 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 3

2

11.1%

Phase 1

1

5.6%

Phase 2

1

5.6%

Trial Status Distribution

Active, not recruiting

15

83.3%

Completed

3

16.7%

Clinical Trials

Trials sponsored by this organization (18)

Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer

720 participants

OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis

80 participants

OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis

Active, not recruiting

Jun 20111,280 participants

OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis

Active, not recruiting

Apr 20111,280 participants

OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis

Active, not recruiting

Mar 20111,280 participants

OASIS: Estudio en fase 2/3, aleatorizado, doble ciego, controlado con placebo de seguridad y eficacia de talactoferrina alfa en pacientes con sepsis grave.OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis. - OASIS

Active, not recruiting

Feb 20111,280 participants

OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis

Active, not recruiting

Feb 20111,280 participants

OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis - OASIS

Active, not recruiting

Feb 20111,280 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials18
Approvals
News

Back to Organizations